Summary
Biogen Idec Inc. (BIIB) filed an 8-K on October 21, 2008, primarily to announce its financial results for the third quarter ended September 30, 2008. The core of this filing is a press release (Exhibit 99.1) which contains the details of the company's operational performance and financial condition. Investors should refer to this press release for specific figures related to revenue, earnings, and any forward-looking statements. While the 8-K itself does not contain the detailed financial data, it officially signifies the public release of this information. The company is presenting these results as required by regulations, and it's important to note the disclaimer that the press release is furnished and not deemed "filed" under Section 18 of the Exchange Act, meaning it doesn't carry the same liability implications for inaccuracies as a formally filed document.
Key Highlights
- 1Biogen Idec announced its third-quarter 2008 financial results on October 21, 2008.
- 2The primary content of the 8-K filing is a press release (Exhibit 99.1) containing the detailed financial and operational results.
- 3Investors should consult the furnished press release for specific quarterly performance metrics.
- 4The filing is a standard procedural update, not an announcement of new material events beyond the quarterly earnings.
- 5The press release is furnished under Item 2.02, and is not deemed 'filed' for the purposes of Section 18 of the Exchange Act.
- 6The report signifies the official public disclosure of Biogen Idec's Q3 2008 financial condition.